User talk:Guilak

A tag has been placed on your user page, User:Guilak, requesting that it be speedily deleted from Wikipedia. This has been done under the criteria for speedy deletion, because the page seems to be blatant advertising which only promotes a company, product, group, service or person, and which is a violation of our policies regarding acceptable use of user pages: user pages are intended for active editors of Wikipedia to communicate with one another as part of the process of creating encyclopedic content, and should not be mistaken for free webhosting resources. Please read the general criteria for speedy deletion, particularly item 11, as well as the guidelines on spam, the guidelines on user pages, and, especially, our FAQ for businesses.

If you can indicate why the page is not blatant advertising, you may contest the tagging. To do this, please add  on the top of the page in question and leave a note on this page explaining your position. Please do not remove the speedy deletion tag yourself. Feel free to leave a note on my talk page if you have any questions about this. Calton | Talk 13:52, 1 January 2009 (UTC)

AfC notification: Draft:Wolfgang Liedtke has a new comment
 I've left a comment on your Articles for Creation submission, which can be viewed at Draft:Wolfgang Liedtke. Thanks! InterstellarGamer12321 ( talk &#124;  contribs ) 09:55, 29 May 2023 (UTC)


 * Thanks so much for the feedback. I deleted a number of references as suggested.  Several others can be easily removed to better conform to Wikipedia guidelines, if needed. Guilak (talk) 22:53, 4 June 2023 (UTC)
 * Thanks so much for your help on this. I took some time to revise as suggested.
 * Notability for an academic in Liedtke's case rests on the following arguments:
 * • Criterion 1 "The person's research has made significant impact in their scholarly discipline, broadly construed, as demonstrated by independent reliable sources."can also be satisfied if the person has ... made a significant discovery in their academic discipline.
 * The case is laid out for Liedtke's initial discovery of the TRPV4 ion channel in 2000, then named vanilloid receptor-related osmotically activated channel (VR-OAC). TRPV4 was the first osmotically-activated ion channel in vertebrate animals. Research on TRPV4 developed into a diverse and dynamic field within the area of TRP ion channel research, of fundamental and medical relevance in physiology. Proper references are now provided: the original discovery paper in CELL Liedtke-et-al, plus two review papers on TRPV4, written by others not related to Liedtke, plus Wiki-links for TRPV4 and TRP ion channels. Of note, the Wikilink for TRPV4 mentions Liedtke's discovery, also key references [5]-[7].
 * • Liedtke is the author of highly cited work.
 * Citation metrics for Liedtke in SCOPUS are provided [updated], for his TRPV4 discovery paper, for his TRPV4-related research, and for all peer reviewed papers that he has published. A reference from Duke University (Wiki-linked notable institution) is provided that clarifies that Liedtke's citation metrics satisfy requirements for "Professure with Tenure", which indeed he was at Duke University from 2016 until he joined Regeneron Pharmaceuticals in April 2021.
 * • Other considerations:
 * Liedtke's significant academic awards and honors: These are now listed with proper references (more detail below; also addressing Criterion 2).
 * Liedtke's service on Editorial Boards of well-established scientific journals: His service on three of these boards is now given with proper references. The journals have the following impact factors. Cancers - 6.6, Neuroscience Bulletin - 5.3, Frontiers in Molecular Neuroscience - 6.3.
 * Liedtke's scholarly publications in prestigious and selective academic journals: Three examples are now referenced, beyond the TRPV4 discovery paper in CELL: Gastroenterology Chen-et-al paper 2021 - Impact Factor 33.9, Nature Communications Lindy-et-al 2014 and Yeo-et-al 2021 papers - Impact Factor Nature Communications 17.7, all three papers with senior and corresponding author Liedtke.
 * Liedtke's publications of collected works: Two frequently cited review papers are now referenced: Moore-et-al paper (180 Scopus citations) in Neuroscience Bulletin 2018 (Impact Factor 5.3), Guilak-et-al paper (1517 Scopus citations) in Cell Stem Cell 2009 (Impact Factor 27.8). In addition, one book that Liedtke edited is referenced "TRP Ion Channel Function in Sensory Transduction and Cellular Signaling Cascades." Editors: Wolfgang B Liedtke and Stefan Heller, published in 2007 by CRC Press/Taylor&Francis, published online by the US National Library of Medicine.
 * Liedtke's role in a special conference: Liedtke was organizer and chairperson of the Conference "20 years of TRPV4", endorsed and supported by the American Physiologic Society, now properly referenced and linked.
 * Liedtke awarded a highly selective fellowship and invited to give prestigious lectures:
 * Liedtke was awarded a Feodor Lynen Fellowship of the Alexander von Humboldt Foundation (Bonn, Germany). The Alexander von Humboldt Foundation as a notable global academic research society is Wiki-linked and the felllowship award properly referenced.
 * Liedtke has been invited to lecture at an upcoming international symposium, one of the Keystone Meetings. The program of the upcoming Keystone Symposium "Somatosensation" (January 2024, Santa Fe NM) is referenced, and Keystone Meetings are linked and referenced.
 * Liedtke gave the Blaustein Pain Lecture at Johns Hopkins University Medical School in 2019, now properly referenced and Johns Hopkins Wiki-linked as notable academic institution.
 * Liedtke's other academic honors: In 2021, Liedtke was elected to the Medical Board of the Facial Pain Association (Suwanee GA). This honor is linked and properly referenced
 * In 2022, Liedtke was elected as external member to the New York University Pain Research Center. This honor is linked and properly referenced, New York College of Dentistry is Wiki-linked as a notable academic institution.
 * • Criterion 2: Academic honors and awards, also supportive of Criterion 1.
 * In 2013, Liedtke was awarded Scholar-Innovator of the Harrington Discovery Institute (Cleveland OH). This award is now properly referenced, the Harrington Discovery Institute linked.
 * In 2004, Liedtke was elected as a Klingenstein Fellow in Neuroscience of the Esther A. and John Klingenstein Fund (New York NY). Of all Klingenstein Fellows, Liedtke was selected the only Robert H. Ebert Clinical Scholar. This award is now properly referenced, the Klingenstein Fund linked.
 * The above evidence is intended to make the point of significant coverage. Wikipedia Notability criteria for academics states: "When judged against the average impact of a researcher in a given field, does this researcher stand out as clearly more notable or more accomplished?" The ensemble of the above evidence, in particular Liedtke's TRPV4 discovery record and its significance for science, his citation record, other considerations as outlined, plus his academic honors and awards, provide a strong "YES" in response to this critical question.
 * The Wikipedia review of the previous submission emphasized that "references need to be published, reliable, secondary, and independent", also that they "not be affiliated with the subject." - Please see next section on references where this critique is specifically addressed 1-by-1.
 * In regards to references:
 * The revised entry now has less than 40 references, of which 19 are new. These references serve the purpose of fulfilling the criteria laid out by Wikipedia to support notability, especially academics' notability: significant coverage of the subject, references need to be published, reliable, secondary, and independent, also not affiliated with the subject Guilak (talk) 16:00, 24 August 2023 (UTC)
 * I think I accidentally submitted the "Wolgang Liedtke" page without saving the new edits and version! The modified text is below. Could you please help in adding this to the page?
 *  Wolfgang Bernhard Liedtke  is a German-American neurologist and molecular neuroscientist. Liedtke is a corporate executive at Regeneron Pharmaceuticals, Tarrytown NY.
 * From 2004-2021, he was a scientist-physician academic professor at Duke University.
 * He was awarded tenure in 2013 and became Full Professor in 2016.  Before Duke University, he was Assistant Professor at The Rockefeller University.
 * He is noted for the first description of the TRPV4 ion channel [originally named vanilloid receptor-related osmotically-activated channel (VR-OAC)], the first vertebrate osmotically-activated ion channel.  This discovery was foundational for subsequent investigations of TRPV4 ion channel biology in the field of TRP ion channel physiology. This field has evolved into a diverse and dynamic research arena, to which Liedtke has made cited contributions (see below). The study of TRPV4 in the field of TRP ion channel research is rooted in Liedtke's discovery of TRPV4. The TRPV4 ion channel is now considered a target for development of therapeutics, including for treatment of pain.   This perspective was discussed in Liedtke's initial discovery paper in 2000, including TRPV4's projected involvement in somatosensation including pain. TRPV4 is also known for its human disease-causing mutations.
 * These mutations cause diseases that affect the developing skeleton to cause skeletal dysplasias, as well as developing motoneurons in the spinal cord to cause spinal muscular atrophies and motor neuropathies. These diseases currently do not have any effective treatment, yet based on Liedtke's original discovery now have a molecular target, TRPV4, for therapeutics development.
 * The original report of TRPV4, published in Cell , is referenced in the peer-reviewed literature: there are 1095 references in SCOPUS (as of June 2023).
 * TRPV4 as the first osmoreceptor molecule in vertebrate animals has been a molecular entity that researchers tried to identify for a considerable time. Liedtke's inaugural discovery of TRPV4 in 2000 was commented upon in Nature Reviews in Neuroscience to illustrate the significance of his discovery: "How do cells respond and adapt to changes in osmotic pressure? It is surprising that our understanding of osmosis from this standpoint is still quite limited. Similarly, although we know that the nervous system is crucial in osmoregulation, controlling the release of vasopressin and the subsequent production of urine, so far we only have a mere glimpse of the brain mechanisms underlying osmoreception. But now, a paper by Liedtke et al. on the cloning of the first osmotically activated channel found in vertebrates could be the breakthrough we needed to get a molecular handle on this problem. The authors identified a vanilloid receptor-related osmotically activated channel (VR-OAC).". A related comment was published in Science Signaling in November 2000.
 * Currently, Liedtke has 104 peer-reviewed scientific publications linked to TRPV4 (SCOPUS as of June 2023). There are currently a total of 2191 TRPV4-linked papers in SCOPUS. With approximately 4.75% of all peer-reviewed publications linked to TRPV4, Liedtke is the most frequent contributor to the field. For comparison, there is no other single author above 55 papers. Liedtke's TRPV4-related work has been referenced 12597 times vs. the entire TRPV4-field 88256 times, thus attributing Liedtke a share of 14.3%. These citation metrics indicate that referencing of his TRPV4-related work is at approximately 3x the percentage of his work of all TRPV4-related original contributions.
 * Liedtke has a total of 149 peer-reviewed papers in SCOPUS (as of June 2023), which have been referenced 14822 times, yielding an h-index of 64. Of the 149 publications, there are 67 papers with Liedtke first or last/corresponding author.
 * Liedtke's citation metrics exceed the requirements for Full Professor with tenure at Duke University.
 * = Three publications out of Liedtke's research laboratory at Duke University illustrate Liedtke's academic discovery record after initial report of TRPV4.  =
 * = Also he published a 2018 review paper on the function of TRP ion channels in pain and itch that was referenced 180 times (SCOPUS as of June 2023), and he was senior co-author on an earlier review paper on mechanobiology of stem cells, related to TRPV4 function as osmo- and mechano-receptor, that was referenced 1517 times (SCOPUS as of June 2023).  Early after setting up his own research laboratory at Duke University, he was Editor of a Taylor&Francis book "TRP ion channel function in sensory transduction and cellular signaling cascades", 31 chapters (one from Liedtke) contributed by international author teams. =
 * In June 2021, a symposium was held "20 years of TRPV4 - Exploring Science, Discovery and Future Directions".
 * This online Symposium (COVID-related not held live in-person) was organized by InsideScientific (Ontario, Canada). It was recognized and officially supported by the American Physiological Society . Liedtke was the Organizer and Program Chair of this meeting of 42 international conference faculty who presented to a global audience. The meeting covered diverse scientific topics of mammalian physiology and human health, including neuroscience, physiology, mechanobiology, cardiovascular, renal-urinary, respiratory, gastrointestinal and skeletal medicine, orthopedics, immunology, infectious disease, human genetics, vision, pain and itch, obstetrics and drug development/biotechnology, the entire spectrum rooted in Liedtke's original discovery of TRPV4.
 * Academic awards and honors
 * The following awards and academic honors for Liedtke are for initial discovery of TRPV4 and subsequent contributions to the scientific and medical field of TRP ion channel biology.
 * • Invited Lecture at Keystone Symposium "Mammalian Somatosensation: Mechanisms of Itch, Touch, Pain and Interoception in Health and Disease." January 14-17, 2024, Santa Fe NM.
 * • Blaustein Pain Lecture at John Hopkins Hospital (Baltimore MD), January 25, 2019.
 * • Harrington Discovery Institute Scholar-Innovator 2013.
 * • Klingenstein Fellow in Neuroscience - Robert H. Ebert Clinical Scholar. Liedtke was the Robert H. Ebert Scholar selected of all Klingenstein Fellows in 2004.
 * The following earlier award was for Liedtke's scholarly and academic excellence.
 * • Feodor Lynen Fellowship of the Alexander von Humboldt Foundation (Bonn, Germany; 1994-1997).
 * Board memberships; scientific journals
 * • Since his election in 2022, Liedtke is an External Member of the New York University Pain Research Center of the New York University College of Dentistry.
 * • Since his election in 2021, Liedtke is a member of the Medical Advisory Board of the Facial Pain Association (Suwanee GA).
 * • Liedtke is an Editorial Board member of the scientific journals, Cancers (Basel, Switzerland) and Neuroscience Bulletin (Shanghai, China), and Associate Editor with Frontiers in Molecular Neuroscience (Lausanne, Switzerland).
 * Early life and education
 * Liedtke, born in Dortmund, Germany, was educated in higher education in Germany, studied medicine at Ruhr University Bochum as a scholar of the German Academic Scholarship Foundation (Studienstiftung des Deutschen Volkes).
 * He earned his MD in 1989 from the University of Cologne and his PhD in 1990 in virology ("Immune Response to Rotavirus Infections in Infants") from Ruhr University Bochum . undefined
 * In 1991 and 1993, he completed residencies in neurology at the University of Tuebingen and at the University of Duisburg-Essen . He then completed a residency in psychiatry at University Hospital and State Psychiatric Hospital, Essen. In 1994, he moved from Germany to the USA for a neuropathology fellowship at Albert Einstein College of Medicine of Yeshiva University in The Bronx NY, as a Feodor Lynen Fellow of the Alexander von Humboldt Foundation.
 * Contributions as a physician
 * From 2004-2021, as a physician in the Duke University Health System, he provided clinical care in his neurology and anesthesiology clinics.
 * Liedtke treated patients suffering from refractory pain, mostly nerve pain of the trigeminal and glossopharyngeal nerve, but also head-face-oral pain and generalized nerve pain. He earned consistently positive patient feedback.
 * For example, patients were stating "Dr. Liedtke is an amazingly intelligent doctor who has given me my life back after treating my refractory trigeminal neuralgia for the past 5 years. There is always a substantial wait time to see him but well worth the wait. I never feel rushed and he takes a considerable amount of time with each patient. I am so grateful for what he has done for me. If you have trigeminal neuralgia, he is THE ONE to see!" and "The most brilliant, kind, and sympathetic doctor I have ever known. Highly, highly recommend. I cannot say enough good things about him and the staff. An above average wait time, but I would wait even longer for him."
 * At Duke University, he was a Distinguished Nominee for the Leonard Tow Humanism in Medicine Award in 2017 and 2018 (Gold Foundation, Englewood Cliffs, NJ).
 * Entrepreneurial contributions
 * The following granted US patents list Liedtke as lead inventor: 9290489, 9701675, 10329265, 11014896, 11229628, 11564911. All intellectual property is rooted in discoveries in Liedtke's Duke research laboratory related to function of TRPV4 in pain and inflammation.
 * Based on the intellectual property, Liedtke co-founded biotechnology company TRPblue Inc.. TRPblue Biotechnology Startup Company, Durham NC; Available from: https://trpblue.com . </ref
 * ==References==
 * ==External links==
 * Guilak (talk) 16:01, 24 August 2023 (UTC)
 * Early life and education
 * Liedtke, born in Dortmund, Germany, was educated in higher education in Germany, studied medicine at Ruhr University Bochum as a scholar of the German Academic Scholarship Foundation (Studienstiftung des Deutschen Volkes).
 * He earned his MD in 1989 from the University of Cologne and his PhD in 1990 in virology ("Immune Response to Rotavirus Infections in Infants") from Ruhr University Bochum . undefined
 * In 1991 and 1993, he completed residencies in neurology at the University of Tuebingen and at the University of Duisburg-Essen . He then completed a residency in psychiatry at University Hospital and State Psychiatric Hospital, Essen. In 1994, he moved from Germany to the USA for a neuropathology fellowship at Albert Einstein College of Medicine of Yeshiva University in The Bronx NY, as a Feodor Lynen Fellow of the Alexander von Humboldt Foundation.
 * Contributions as a physician
 * From 2004-2021, as a physician in the Duke University Health System, he provided clinical care in his neurology and anesthesiology clinics.
 * Liedtke treated patients suffering from refractory pain, mostly nerve pain of the trigeminal and glossopharyngeal nerve, but also head-face-oral pain and generalized nerve pain. He earned consistently positive patient feedback.
 * For example, patients were stating "Dr. Liedtke is an amazingly intelligent doctor who has given me my life back after treating my refractory trigeminal neuralgia for the past 5 years. There is always a substantial wait time to see him but well worth the wait. I never feel rushed and he takes a considerable amount of time with each patient. I am so grateful for what he has done for me. If you have trigeminal neuralgia, he is THE ONE to see!" and "The most brilliant, kind, and sympathetic doctor I have ever known. Highly, highly recommend. I cannot say enough good things about him and the staff. An above average wait time, but I would wait even longer for him."
 * At Duke University, he was a Distinguished Nominee for the Leonard Tow Humanism in Medicine Award in 2017 and 2018 (Gold Foundation, Englewood Cliffs, NJ).
 * Entrepreneurial contributions
 * The following granted US patents list Liedtke as lead inventor: 9290489, 9701675, 10329265, 11014896, 11229628, 11564911. All intellectual property is rooted in discoveries in Liedtke's Duke research laboratory related to function of TRPV4 in pain and inflammation.
 * Based on the intellectual property, Liedtke co-founded biotechnology company TRPblue Inc.. TRPblue Biotechnology Startup Company, Durham NC; Available from: https://trpblue.com .  I've left a comment on your Articles for Creation submission, which can be viewed at Draft:Wolfgang Liedtke. Thanks! – bradv  21:36, 29 May 2023 (UTC)


 * Thanks, I did not add a birthdate as several colleagues with Wikipedia pages felt that it was a risk for identity theft to have that personal information posted. Guilak (talk) 22:54, 4 June 2023 (UTC)

AfC notification: Draft:Wolfgang Liedtke has a new comment
 I've left a comment on your Articles for Creation submission, which can be viewed at Draft:Wolfgang Liedtke. Thanks! ~Kvng (talk) 23:24, 4 June 2023 (UTC)

Your submission at Articles for creation: Wolfgang Liedtke (June 7)
 Your recent article submission to Articles for Creation has been reviewed! Unfortunately, it has not been accepted at this time. The reason left by Carpimaps was:

The comment the reviewer left was:

Please check the submission for any additional comments left by the reviewer. You are encouraged to edit the submission to address the issues raised and resubmit after they have been resolved.


 * If you would like to continue working on the submission, go to Draft:Wolfgang Liedtke and click on the "Edit" tab at the top of the window.
 * If you do not edit your draft in the next 6 months, it will be considered abandoned and may be deleted.
 * If you need any assistance, or have experienced any untoward behavior associated with this submission, you can ask for help at the [//en.wikipedia.org/w/index.php?title=Wikipedia:WikiProject_Articles_for_creation/Help_desk/New_question&withJS=MediaWiki:AFCHD-wizard.js&page=Draft:Wolfgang_Liedtke Articles for creation help desk], on the [//en.wikipedia.org/w/index.php?title=User_talk:Carpimaps&action=edit&section=new&nosummary=1&preload=Template:AfC_decline/HD_preload&preloadparams%5B%5D=Draft:Wolfgang_Liedtke reviewer's talk page] or use Wikipedia's real-time chat help from experienced editors.

Carpimaps talk to me! 14:38, 7 June 2023 (UTC)

Your submission at Articles for creation: Wolfgang Liedtke (September 9)
 Your recent article submission to Articles for Creation has been reviewed. Unfortunately, it has not been accepted at this time. The reason left by Utopes was:

The comment the reviewer left was:

Please check the submission for any additional comments left by the reviewer. You are encouraged to edit the submission to address the issues raised and resubmit after they have been resolved.


 * If you would like to continue working on the submission, go to Draft:Wolfgang Liedtke and click on the "Edit" tab at the top of the window.
 * If you do not edit your draft in the next 6 months, it will be considered abandoned and may be deleted.
 * If you need any assistance, or have experienced any untoward behavior associated with this submission, you can ask for help at the [//en.wikipedia.org/w/index.php?title=Wikipedia:WikiProject_Articles_for_creation/Help_desk/New_question&withJS=MediaWiki:AFCHD-wizard.js&page=Draft:Wolfgang_Liedtke Articles for creation help desk], on the [//en.wikipedia.org/w/index.php?title=User_talk:Utopes&action=edit&section=new&nosummary=1&preload=Template:AfC_decline/HD_preload&preloadparams%5B%5D=Draft:Wolfgang_Liedtke reviewer's talk page] or use Wikipedia's real-time chat help from experienced editors.

Utopes (talk / cont) 07:31, 9 September 2023 (UTC)

Concern regarding Draft:Wolfgang Liedtke
Hello, Guilak. This is a bot-delivered message letting you know that Draft:Wolfgang Liedtke, a page you created, has not been edited in at least 5 months. Drafts that have not been edited for six months may be deleted, so if you wish to retain the page, please edit it again&#32;or request that it be moved to your userspace.

If the page has already been deleted, you can request it be undeleted so you can continue working on it.

Thank you for your submission to Wikipedia. FireflyBot (talk) 13:06, 29 April 2024 (UTC)